Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    YH003002
Previous Study | Return to List | Next Study

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04481009
Recruitment Status : Not yet recruiting
First Posted : July 22, 2020
Last Update Posted : July 22, 2020
Sponsor:
Information provided by (Responsible Party):
Eucure (Beijing) Biopharma Co., Ltd

Brief Summary:
This is a phase I/II, multi-center, open-label study of YH003 in combination with Toripalimab (anti-PD-1 mAb). The study is comprised of a dose escalation part (Part I) exploring escalating doses of YH003 in combination with fixed dose toripalimab in subjects with advanced solid tumors (Part I), followed by an expansion part (Part II) with three expansion cohorts.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: YH003 Drug: Toripalimab Drug: Nab-paclitaxel Drug: Gemcitabine Phase 1 Phase 2

Detailed Description:

The study is comprised of a dose escalation part (Part I) exploring escalating doses of YH003 in combination with fixed dose toripalimab in subjects with advanced solid tumors (Part I), followed by an expansion part (Part II) with three expansion cohorts.

During Part I, dose escalation part of the study, a traditional 3+3 dose algorithm will be utilized to identify MTD(maximum tolerated dose) and/or RP2D (recommended phase 2 dose).

This dose escalation part will consist two phases, the run-in phase to explore safety and tolerability of YH003 as single agent and the combination phase to explore safety and tolerability of escalating doses of YH003 in combination with fixed dose Toripalimab.

The Phase II expansion part of this clinical trial will include three parallel cohorts(cohort 2A, 2B and 2C) of 20 subjects each treated with a dose around the RP2D of YH003 in combination with Toripalimab to assess the antitumor activity and safety/tolerability. One expansion cohort (2A) is YH003 and toripalimab in subjects with unresectable/metastatic melanoma, the other two expansion cohorts (2B and 2C) are YH003 and toripalimab with or without nab-paclitaxel + gemcitabine in unresectable/ metastatic pancreatic ductal adenocarcinoma.

Subjects will be monitored for safety, tolerability and efficacy throughout the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
Estimated Study Start Date : July 2020
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : March 2023

Arm Intervention/treatment
Experimental: YH003 with Toripalimab after PD-1/L1 +/- CTLA-4 treatment
YH003 in combination with Toripalimab in subjects with unresectable /metastatic melanoma after having failed PD-1/L1 +/- CTLA-4 treatment.
Drug: YH003
YH003 will be administered intravenously over 60 minutes every 21-day cycle.

Drug: Toripalimab
Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.

Experimental: YH003 with Toripalimab in subjects with PDAC
YH003 in combination with Toripalimab in subjects with unresectable/ metastatic pancreatic ductal adenocarcinoma (PDAC) as 2nd line treatment.
Drug: YH003
YH003 will be administered intravenously over 60 minutes every 21-day cycle.

Drug: Toripalimab
Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.

Experimental: YH003 with Toripalimab plus standard chemotherapy
YH003 in combination with Toripalimab plus standard chemotherapy (Nab-paclitaxel + Gemcitabine) in subjects with unresectable/metastatic PDAC as 1st line treatment
Drug: YH003
YH003 will be administered intravenously over 60 minutes every 21-day cycle.

Drug: Toripalimab
Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.

Drug: Nab-paclitaxel
Nab-paclitaxel will be administered each 21-day cycle.

Drug: Gemcitabine
Gemcitabine will be administrated each 21-day cycle.




Primary Outcome Measures :
  1. Overall safety and tolerability profile of YH003 in combination with Toripalimab. [ Time Frame: From screening up to 1 year ]
    The safety profile of YH003 in combination with Toripalimab will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0

  2. Maximum tolerated dose (MTD) and Recommended phase 2 dose (RP2D) [ Time Frame: Cycle 1 of each cohort. Duration of one cycle is 3 weeks ]
    The MTD and RP2D will be determined based on the data of safety and tolerability


Secondary Outcome Measures :
  1. Area under the serum concentration versus time curve (AUC) [ Time Frame: Up to 1 year ]
    To determine the PK profile of YH003 alone and in combination with Toripalimab

  2. Maximum serum concentration (Cmax) [ Time Frame: Up to 1 year ]
    To determine the PK profile of YH003 alone and in combination with Toripalimab

  3. Trough concentration before the next dose is administered (Ctrough) [ Time Frame: Up to 1 year ]
    To determine the PK profile of YH003 alone and in combination with Toripalimab

  4. Time to reach maximum serum concentration (Tmax) [ Time Frame: Up to 1 year ]
    To determine the PK profile of YH003 alone and in combination with Toripalimab

  5. Clearance (CL) [ Time Frame: Up to 1 year ]
    To determine the PK profile of YH003 alone and in combination with Toripalimab

  6. Volume of distribution (Vd) [ Time Frame: Up to 1 year ]
    To determine the PK profile of YH003 alone and in combination with Toripalimab

  7. Volume of distribution at steady state (Vss) [ Time Frame: Up to 1 year ]
    To determine the PK profile of YH003 alone and in combination with Toripalimab

  8. Terminal half-life (T1/2) [ Time Frame: Up to 1 year ]
    To determine the PK profile of YH003 alone and in combination with Toripalimab

  9. Dose proportionality [ Time Frame: Up to 1 year ]
    To determine the PK profile of YH003 alone and in combination with Toripalimab

  10. Incidence of anti-drug antibodies (ADAs) [ Time Frame: Up to 1 year ]
    To assess the immunogenicity of YH003 in combination with Toripalimab

  11. Incidence of neutralizing antibodies (NAbs) [ Time Frame: Up to 1 year ]
    To assess the immunogenicity of YH003 in combination with Toripalimab

  12. Objective response rate (ORR) [ Time Frame: Up to 1 year ]
    To assess the preliminary antitumor activity of YH003 in combination with Toripalimab

  13. Duration of response (DOR) [ Time Frame: Up to 1 year ]
    To assess the preliminary antitumor activity of YH003 in combination with Toripalimab

  14. Time to response (TTR) [ Time Frame: Up to 1 year ]
    To assess the preliminary antitumor activity of YH003 in combination with Toripalimab

  15. Progression free survival (PFS) [ Time Frame: Up to 1 year ]
    To assess the preliminary antitumor activity of YH003 in combination with Toripalimab

  16. Overall survival (OS) [ Time Frame: Up to 1 year ]
    To assess the preliminary antitumor activity of YH003 in combination with Toripalimab

  17. Disease control rate (DCR) [ Time Frame: Up to 1 year ]
    To assess the preliminary antitumor activity of YH003 in combination with Toripalimab

  18. Duration of disease control (DDC) [ Time Frame: Up to 1 year ]
    To assess the preliminary antitumor activity of YH003 in combination with Toripalimab



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects must have the ability to understand and willingness to sign a written informed consent document.
  2. Part I dose escalation:

    Have histologically advanced or cytologically confirmed solid tumor. Have progressed on after treatment with at least one standard therapy or intolerant of the standard therapy.

    Part II dose expansion:

    Cohort 2A: Histologically or cytologically confirmed unresectable or metastatic melanoma that had confirmed progressive disease during treatment with an anti-PD-1/PD-L1 therapy with or without additional CTLA-4 therapy. Subjects with BRAF activating mutation could have also received a BRAF inhibitor and/or MEK inhibitor regimen prior to anti-PD-1/PD-L1 therapy.

    Cohort 2B, 2C: Subject has histologically or cytologically documented diagnosis of pancreatic ductal adenocarcinoma with unresectable locally advanced/metastatic disease Cohort 2B: had confirmed progressive disease during treatment with first line standard of care of chemotherapy per local standard.

    Cohort 2C: treatment-naïve for unresectable locally advanced/metastatic disease.

  3. Subject must have measurable disease by RECIST 1.1. At least 1 unidimensional measurable target lesion per RECIST v1.1 for study Part II expansion cohorts.
  4. Subjects must be age 18 years or older.
  5. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Life expectancy ≥3 months.
  6. Subjects must have adequate organ function.
  7. Women of reproductive potential must have negative serum beta human chorionic gonadotropin (β -HCG) pregnancy test.

Exclusion Criteria:

  1. Part II Cohort 2A: History of life-threatening toxicity or treatment discontinuation due to related to prior anti-PD-1/PD-L1 and with or without CTLA-4 combination treatment for subjects with unresectable/metastatic melanoma.
  2. Subjects must not have another active invasive malignancy.
  3. Previous exposure to TNFR such as anti-CD137, OX40, CD27 and CD357 antibodies.
  4. Subjects must not have received any anticancer therapy or another investigational agent within the shorter of 4 weeks or 5 half-lives before the first dose of the study treatment.
  5. Subjects with a history of ≥ Grade 3 immune-related adverse events resulted from previous immunotherapy.
  6. History of clinically significant sensitivity or allergy to monoclonal antibodies and their excipients or known allergies to antibodies produced from Chinese hamster ovary cells, which in the opinion of the Investigator suggests an increased potential for an adverse hypersensitivity to YH003 or Toripalimab. Also history of severe hypersensitivity reaction to Nap-paclitaxel and/or gemcitabine.
  7. Primary central nervous system (CNS) malignancies or symptomatic CNS metastases.
  8. History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis, or history of interstitial lung disease.
  9. Subjects must not have a known or suspected history of an autoimmune disorder, including but not limited to inflammatory bowel disease, celiac disease, Wegner syndrome, Hashimoto syndrome, systemic lupus erythematosus, scleroderma, sarcoidosis, or autoimmune hepatitis, within 3 years of the first dose of study treatment.
  10. Clinically uncontrolled intercurrent illness, including an ongoing or active infection, active coagulopathy, uncontrolled diabetes, psychiatric illness that would limit compliance with the study requirements and other serious medical illnesses requiring systemic therapies.
  11. Severe cardiovascular disease including symptomatic congestive heart failure (New York Heart Association class III or IV), unstable angina, uncontrolled hypertension, cardiac arrhythmia, a history of myocardial infarction within 6 months or a history of arterial thromboembolic event and pulmonary embolism within 3 months of the first dose of investigational agent.
  12. QTc > 450 ms at baseline; no concomitant medications that would prolong the QT interval; no family history of long QT syndrome.
  13. Subjects must not have active infection of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
  14. Subjects must not have a history of primary immunodeficiency.
  15. Subjects from endemic area will be specifically screened for tuberculosis. Subjects with active tuberculosis are excluded.
  16. Subjects must not receive concurrent or prior use of an immunosuppressive agent within 4 weeks of the first dose of YH003.
  17. Major surgery within 4 weeks prior to study entry and Minor surgery within 2 weeks prior to the first dose of YH003.
  18. Subjects must not have received a live attenuated vaccine within 28 days before the first dose of YH003, and subjects, if enrolled, should not receive live vaccines during the study or for 180 days after the last dose of YH003.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04481009


Contacts
Layout table for location contacts
Contact: Ryan Wen +8618910639682 ext +8618910639682 ryan.wen@eucure.com

Sponsors and Collaborators
Eucure (Beijing) Biopharma Co., Ltd
Layout table for additonal information
Responsible Party: Eucure (Beijing) Biopharma Co., Ltd
ClinicalTrials.gov Identifier: NCT04481009    
Other Study ID Numbers: YH003002
First Posted: July 22, 2020    Key Record Dates
Last Update Posted: July 22, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Gemcitabine
Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs